GlobeNewswire Inc | Sep 10, 2020 04:25PM EDT

September 10, 2020

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the Investor Relations page of theWave Life Sciencescorporate website at http://ir.wavelifesciences.com.A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the companys proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contacts:Kate Rausch 617-949-4827 krausch@wavelifesci.com

Graham Morrell 781-686-9600 gmorrell@wavelifesci.com

Media Contact:Alicia Suter617-949-4817asuter@wavelifesci.com